Technetium-99m Tetrofosmin in Myocardial Perfusion Imaging: A Cornerstone in Cardiac Diagnostics

Technetium-99m tetrofosmin, commercially known as Myoview, represents a significant advancement in the field of nuclear cardiology, particularly in the imaging of myocardial perfusion. This radiopharmaceutical agent is pivotal in diagnosing and managing various cardiac conditions, especially coronary artery disease (CAD). Its properties, mechanism of action, and application in myocardial perfusion imaging (MPI) offer clinicians a sophisticated tool to assess the heart’s blood flow and function. In this comprehensive overview, we will delve into the nuances of Technetium-99m tetrofosmin, exploring its chemistry, diagnostic utility, and the implications it has for patient care.

Chemistry and Pharmacokinetics

Technetium-99m (Tc-99m) is a metastable nuclear isomer of technetium-99, and it emits gamma rays that a gamma camera can detect. This radioisotope has ideal characteristics for medical imaging due to its relatively short half-life of approximately 6 hours, which minimises radiation exposure to the patient, and its emission of gamma rays at an energy level (140 keV) that is easily detected by standard nuclear medicine cameras.

Tetrofosmin is an organophosphorus compound that chelates with Tc-99m. When labelled with Tc-99m, tetrofosmin becomes a lipophilic complex that can cross cell membranes and is temporarily lodged in the mitochondrial rich cells of myocardial tissue, allowing for effective heart imaging. The preparation of Tc-99m tetrofosmin is relatively straightforward, requiring only a generator of Tc-99m and a kit containing the tetrofosmin compound for labelling.

Mechanism of Action

After intravenous injection, Tc-99m tetrofosmin quickly distributes in the bloodstream and is taken up by myocardial cells in proportion to blood flow. It enters the cells via passive diffusion, driven by the concentration gradient, and binds to intracellular components, primarily mitochondria, given its lipophilic nature. The uptake and retention of Tc-99m tetrofosmin by myocardial cells provide a means to visualise blood flow distribution to the heart muscle.

The radiotracer’s uptake is flow-dependent, which means that areas with good blood supply will show higher uptake, while areas with reduced perfusion, such as those supplied by narrowed or blocked coronary arteries, will exhibit less uptake. This differential uptake allows for the identification of ischemic regions, where blood flow is compromised, versus infarcted areas, where there is tissue death.

Diagnostic Application

The primary application of Tc-99m tetrofosmin is in MPI, which is a non-invasive diagnostic procedure that provides images representing the distribution of blood flow in the heart. MPI with Tc-99m tetrofosmin can be performed either at rest or during stress, which is induced by exercise or pharmacologically to increase the demand for blood flow in the heart and uncover any potential supply deficits indicative of CAD.

Stress and rest images are compared to assess for any perfusion defects that may indicate areas of reversible ischemia or fixed defects consistent with myocardial scarring. The ability to visualise these defects can guide clinical decision-making regarding the need for further diagnostic procedures, such as coronary angiography, or therapeutic interventions, including medication adjustments, angioplasty, or bypass surgery.

Advantages Over Other Agents

Tc-99m tetrofosmin has several advantages over other radiopharmaceuticals used in MPI. It has rapid myocardial uptake and favourable redistribution kinetics, which allow for high-quality imaging within a short time frame after injection. Its rapid clearance from non-cardiac tissue, particularly the liver, provides excellent contrast between the heart and surrounding organs, facilitating the interpretation of MPI scans. Additionally, the lower radiation dose compared to other imaging agents is beneficial for patient safety, particularly in populations that require serial imaging.

Safety Profile

Tc-99m tetrofosmin has a proven safety profile. Adverse reactions are rare, and when they do occur, they are typically mild and transient. Allergic reactions are exceptionally uncommon. The low radiation burden associated with Tc-99m tetrofosmin is an important consideration, as it reduces the risk of radiation-induced complications, making it a preferable choice for repeated examinations when necessary.

Clinical Impact

The clinical impact of MPI with Tc-99m tetrofosmin is substantial. It offers critical insights into the presence and extent of CAD, assists in risk stratification, and aids in the prognosis of patients with known or suspected heart disease. For instance, a normal MPI scan can indicate a low risk of cardiac events, providing reassurance to both the patient and the physician. On the contrary, abnormal findings can prompt timely interventions that might prevent serious cardiac events, such as myocardial infarctions or sudden cardiac death.

Future Directions

Ongoing research in nuclear cardiology continues to expand the applications of Tc-99m tetrofosmin. This includes studies on its utility in conditions beyond CAD, such as heart failure, where myocardial perfusion patterns can provide valuable prognostic information. Advances in imaging technology and software also enhance the diagnostic capabilities of Tc-99m tetrofosmin MPI, potentially offering more quantitative and precise assessments of myocardial perfusion and function.


Technetium-99m tetrofosmin (Myoview) is a cornerstone in diagnosing and managing cardiac disease, particularly through the lens of MPI. Its sophisticated chemistry, ease of use, and superior safety and imaging characteristics make it an indispensable tool in the realm of nuclear cardiology. As healthcare continues to evolve, the role of Tc-99m tetrofosmin is likely to expand, reinforcing its status as a key agent in the visualisation and understanding of cardiac physiology and pathology.

You Are Here: Home » technetium-99m tetrofosmin
Tags: Heart Imaging, Myoview, Technetium Radiopharmaceuticals
Open Medscience